These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 38114758)

  • 21. Evaluation of patient reporting of adverse drug reactions to the UK 'Yellow Card Scheme': literature review, descriptive and qualitative analyses, and questionnaire surveys.
    Avery AJ; Anderson C; Bond CM; Fortnum H; Gifford A; Hannaford PC; Hazell L; Krska J; Lee AJ; McLernon DJ; Murphy E; Shakir S; Watson MC
    Health Technol Assess; 2011 May; 15(20):1-234, iii-iv. PubMed ID: 21545758
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety of pitolisant: a study in the WHO international pharmacovigilance database.
    Montastruc JL
    Eur J Clin Pharmacol; 2023 Apr; 79(4):569-570. PubMed ID: 36892631
    [No Abstract]   [Full Text] [Related]  

  • 23. Adverse drug reactions in neonates: could we be documenting more?
    Hawcutt DB; O'Connor O; Turner MA
    Expert Rev Clin Pharmacol; 2014 Nov; 7(6):807-20. PubMed ID: 25225053
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The ISoP CommSIG for Improving Medicinal Product Risk Communication: A New Special Interest Group of the International Society of Pharmacovigilance.
    Bahri P; Dodoo AN; Edwards BD; Edwards IR; Fermont I; Hagemann U; Hartigan-Go K; Hugman B; Mol PG
    Drug Saf; 2015 Jul; 38(7):621-7. PubMed ID: 26032946
    [No Abstract]   [Full Text] [Related]  

  • 25. Identification of risk factors for adverse drug reactions in a pharmacovigilance database.
    Attelind S; Eriksson N; Sundström A; Wadelius M; Hallberg P
    Pharmacoepidemiol Drug Saf; 2024 Jan; 33(1):e5753. PubMed ID: 38169128
    [No Abstract]   [Full Text] [Related]  

  • 26. [Recording and assessment of medication errors : Experience of the Drug Commission of the German Medical Association].
    Köberle U; Stammschulte T; Gundert-Remy U; Pitzer M; Bräutigam K
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2018 Sep; 61(9):1066-1074. PubMed ID: 30022236
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Artificial intelligence in pharmacovigilance: A regulatory perspective on explainability.
    Pinheiro LC; Kurz X
    Pharmacoepidemiol Drug Saf; 2022 Dec; 31(12):1308-1310. PubMed ID: 35959980
    [No Abstract]   [Full Text] [Related]  

  • 28. Drug-Drug Interactions: A Pharmacovigilance Road Less Traveled.
    Price J
    Clin Ther; 2023 Feb; 45(2):94-98. PubMed ID: 36641261
    [No Abstract]   [Full Text] [Related]  

  • 29. Systematic collection of patient-reported adverse drug reactions: a path to patient-centred pharmacovigilance.
    Basch E
    Drug Saf; 2013 Apr; 36(4):277-8. PubMed ID: 23508543
    [No Abstract]   [Full Text] [Related]  

  • 30. Bismuth and pharmacovigilance.
    Trenque T
    Therapie; 2021; 76(5):383-384. PubMed ID: 33218671
    [No Abstract]   [Full Text] [Related]  

  • 31. [The position and importance of pharmacovigilance in the Czech Republic and in the world].
    Zatovkaňuková P; Slíva J
    Vnitr Lek; 2022; 68(E-4):10-15. PubMed ID: 36220372
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Estimation of adverse drug reaction reporting in Iran: Correction for underreporting.
    Khalili M; Mesgarpour B; Sharifi H; Golozar A; Haghdoost AA
    Pharmacoepidemiol Drug Saf; 2021 Aug; 30(8):1101-1114. PubMed ID: 33772938
    [TBL] [Abstract][Full Text] [Related]  

  • 33. When I use a word . . . Medical definitions: Pharmacovigilance.
    Aronson JK
    BMJ; 2023 Apr; 381():855. PubMed ID: 37059463
    [No Abstract]   [Full Text] [Related]  

  • 34. [From pharmacovigilance to pharmacoepidemiology and risk coordination].
    Montastruc JL
    Rev Med Interne; 2009 Dec; 30 Suppl 4():S281-90. PubMed ID: 19892443
    [No Abstract]   [Full Text] [Related]  

  • 35. Adverse Drug Reaction Reports Received Through the Mobile App, VigiBIP
    Montastruc F; Bagheri H; Lacroix I; Damase-Michel C; Chebane L; Rousseau V; Jouanjus E; Lapeyre-Mestre M; Durrieu G; Montastruc JL
    Drug Saf; 2018 May; 41(5):511-514. PubMed ID: 29270770
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacovigilance in China: development and challenges.
    Zhao Y; Wang T; Li G; Sun S
    Int J Clin Pharm; 2018 Aug; 40(4):823-831. PubMed ID: 30051225
    [TBL] [Abstract][Full Text] [Related]  

  • 37. When I use a word . . . Medical definitions: Pharmacovigilance signals.
    Aronson JK
    BMJ; 2023 May; 381():1032. PubMed ID: 37146998
    [No Abstract]   [Full Text] [Related]  

  • 38. Annual review of pharmacovigilance.
    Diesel G; Cooles S
    Vet Rec; 2018 Jul; 183(2):72. PubMed ID: 30002183
    [No Abstract]   [Full Text] [Related]  

  • 39. Towards Drug Safety Surveillance and Pharmacovigilance: Current Progress in Detecting Medication and Adverse Drug Events from Electronic Health Records.
    Liu F; Jagannatha A; Yu H
    Drug Saf; 2019 Jan; 42(1):95-97. PubMed ID: 30649734
    [No Abstract]   [Full Text] [Related]  

  • 40. The value of case reports in pharmacovigilance.
    Garcia-Doval I; Segovia E; Hunter H; Frew J; Naldi L
    Br J Dermatol; 2020 Nov; 183(5):795-796. PubMed ID: 33135791
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.